company background image
PRCT logo

PROCEPT BioRobotics NasdaqGM:PRCT Stock Report

Last Price

US$48.84

Market Cap

US$2.5b

7D

0.6%

1Y

78.2%

Updated

27 Mar, 2024

Data

Company Financials +

PROCEPT BioRobotics Corporation

NasdaqGM:PRCT Stock Report

Market Cap: US$2.5b

PRCT Stock Overview

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally.

PRCT fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

PROCEPT BioRobotics Corporation Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PROCEPT BioRobotics
Historical stock prices
Current Share PriceUS$48.84
52 Week HighUS$52.32
52 Week LowUS$24.83
Beta1.02
1 Month Change0%
3 Month Change13.71%
1 Year Change78.25%
3 Year Changen/a
5 Year Changen/a
Change since IPO16.45%

Recent News & Updates

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Recent updates

US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Mar 01
US$56.67 - That's What Analysts Think PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Is Worth After These Results

Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Feb 07
Despite Lacking Profits PROCEPT BioRobotics (NASDAQ:PRCT) Seems To Be On Top Of Its Debt

Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Dec 14
Market Participants Recognise PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) Revenues Pushing Shares 26% Higher

Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Feb 27
Is There An Opportunity With PROCEPT BioRobotics Corporation's (NASDAQ:PRCT) 43% Undervaluation?

Procept Biorobotics announces $52M debt refinancing

Oct 10

Providence announces national contract for PROCEPT Biorobotics Aquabeam Systems

Sep 19

Procept BioRobotics Has Resources To Ramp Up Commercialization

Sep 01

Procept: Leveraging A Novel Water-Based System For Enlarged Prostate Treatment

May 26

Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

May 10
Need To Know: Analysts Are Much More Bullish On PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Revenues

PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Mar 10
PROCEPT BioRobotics Corporation (NASDAQ:PRCT) Just Reported, And Analysts Assigned A US$41.00 Price Target

Shareholder Returns

PRCTUS Medical EquipmentUS Market
7D0.6%2.2%0.4%
1Y78.2%13.3%28.8%

Return vs Industry: PRCT exceeded the US Medical Equipment industry which returned 12% over the past year.

Return vs Market: PRCT exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is PRCT's price volatile compared to industry and market?
PRCT volatility
PRCT Average Weekly Movement6.6%
Medical Equipment Industry Average Movement7.7%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: PRCT has not had significant price volatility in the past 3 months.

Volatility Over Time: PRCT's weekly volatility (7%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2007626Reza Zadnohttps://www.procept-biorobotics.com

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH.

PROCEPT BioRobotics Corporation Fundamentals Summary

How do PROCEPT BioRobotics's earnings and revenue compare to its market cap?
PRCT fundamental statistics
Market capUS$2.49b
Earnings (TTM)-US$105.90m
Revenue (TTM)US$136.19m

18.3x

P/S Ratio

-23.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
PRCT income statement (TTM)
RevenueUS$136.19m
Cost of RevenueUS$65.14m
Gross ProfitUS$71.05m
Other ExpensesUS$176.95m
Earnings-US$105.90m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.08
Gross Margin52.17%
Net Profit Margin-77.76%
Debt/Equity Ratio19.0%

How did PRCT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.